On the other hand, a number of independent studies confirmed PD1 efficacy in reducing the oxidative stress in other pathologies, including a cellular model of Parkinson's disease [101], diabetes [102], and stroke [88]; yet, to date, a single investigation demonstrated the effect of PDX on reducing the oxidative burst in neutrophils through the inhibition of NOX and myeloperoxidase (MPO) [103]. Here, MPO is linked to diabetes mellitus.